{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:52Z","timestamp":1792090012390,"version":"4.4.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00520-026-11289-3","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:31:34Z","timestamp":1791005494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of osteoporosis and low bone mass in men with prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"34","author":[{"given":"Mehdi","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolreza","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sogand","family":"Sarmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Rahimnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Zare-Kaseb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Olivia","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza Namazi","family":"Shabestari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Sanaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbasali","family":"Keshtkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad Kazem","family":"Aghamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"2","key":"11289_CR1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2022","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O et al (2022) 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol 84(2):191\u2013206","journal-title":"Eur Urol"},{"issue":"2","key":"11289_CR2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63","journal-title":"World J Oncol"},{"issue":"1","key":"11289_CR3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77(1):38\u201352","journal-title":"Eur Urol"},{"issue":"2","key":"11289_CR4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2022","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O et al (2022) 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol 84(2):191\u2013206","journal-title":"Eur Urol"},{"issue":"2","key":"11289_CR5","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3390\/curroncol30020178","volume":"30","author":"CV Berenguer","year":"2023","unstructured":"Berenguer CV, Pereira F, C\u00e2mara JS, Pereira JAM (2023) Underlying features of prostate cancer\u2014statistics, risk factors, and emerging methods for its diagnosis. Curr Oncol 30(2):2300\u20132321","journal-title":"Curr Oncol"},{"issue":"2","key":"11289_CR6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/1078-0432.CCR-21-2577","volume":"28","author":"KH Stopsack","year":"2022","unstructured":"Stopsack KH, Nandakumar S, Arora K, Nguyen B, Vasselman SE, Nweji B et al (2022) Differences in prostate cancer genomes by self-reported race: contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors. Clin Cancer Res 28(2):318\u2013326","journal-title":"Clin Cancer Res"},{"issue":"3","key":"11289_CR7","doi-asserted-by":"crossref","first-page":"e222246\u2013e","DOI":"10.1001\/jamanetworkopen.2022.2246","volume":"5","author":"MM Desai","year":"2022","unstructured":"Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A et al (2022) Trends in incidence of metastatic prostate cancer in the US. JAMA Net Open 5(3):e222246-e","journal-title":"JAMA Net Open"},{"issue":"3","key":"11289_CR8","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2022) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"11289_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00774-023-01414-1","volume":"41","author":"S Takahashi","year":"2023","unstructured":"Takahashi S (2023) Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer. J Bone Miner Metab 41(3):307\u2013316","journal-title":"J Bone Miner Metab"},{"issue":"11","key":"11289_CR10","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1007\/s12094-022-02872-1","volume":"24","author":"S Casta\u00f1eda","year":"2022","unstructured":"Casta\u00f1eda S, Casas A, Gonz\u00e1lez-del-Alba A, Mart\u00ednez-D\u00edaz-Guerra G, Nogu\u00e9s X, Ojeda Thies C et al (2022) Bone loss induced by cancer treatments in breast and prostate cancer patients. Clin Transl Oncol 24(11):2090\u20132106","journal-title":"Clin Transl Oncol"},{"key":"11289_CR11","first-page":"87","volume":"14","author":"E Choi","year":"2022","unstructured":"Choi E, Buie J, Camacho J, Sharma P, de Riese WTW (2022) Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Res Rep Urol 14:87\u2013108","journal-title":"Res Rep Urol"},{"issue":"2","key":"11289_CR12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","volume":"23","author":"AU Kishan","year":"2022","unstructured":"Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A et al (2022) Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol 23(2):304\u2013316","journal-title":"Lancet Oncol"},{"issue":"1","key":"11289_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89589-3","volume":"11","author":"DK Kim","year":"2021","unstructured":"Kim DK, Lee HS, Park J-Y, Kim JW, Ahn HK, Ha JS et al (2021) Androgen-deprivation therapy and the risk of newly developed fractures in patients with prostate cancer: a nationwide cohort study in Korea. Sci Rep 11(1):10057","journal-title":"Sci Rep"},{"key":"11289_CR14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100465","volume":"38","author":"MM van Oostwaard","year":"2023","unstructured":"van Oostwaard MM, van den Bergh JP, van de Wouw Y, Janssen-Heijnen M, de Jong M, Wyers CE (2023) High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer. J Bone Oncol 38:100465","journal-title":"J Bone Oncol"},{"issue":"1","key":"11289_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73598-z","volume":"14","author":"C-Y Lin","year":"2024","unstructured":"Lin C-Y, Wang C-L, Yang C-K, Li J-R, Chen C-S, Chiu K-Y et al (2024) The impact of novel hormonal agents on fracture risk in prostate cancer patients: a nationwide population-based cohort study. Sci Rep 14(1):26696","journal-title":"Sci Rep"},{"issue":"1","key":"11289_CR16","volume":"18","author":"W-C Chen","year":"2023","unstructured":"Chen W-C, Li J-R, Wang S-S, Chen C-S, Cheng C-L, Hung S-C et al (2023) Conventional androgen deprivation therapy is associated with an increased risk of fracture in advanced prostate cancer, a nationwide population-based study. PLoS ONE 18(1):e0279981","journal-title":"PLoS ONE"},{"issue":"1","key":"11289_CR17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbspin.2018.09.017","volume":"86","author":"K Briot","year":"2019","unstructured":"Briot K, Paccou J, Beuzeboc P, Bonneterre J, Bouvard B, Confavreux CB et al (2019) French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. Jt Bone Spine 86(1):21\u201328","journal-title":"Jt Bone Spine"},{"issue":"3","key":"11289_CR18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(02)01560-1","volume":"60","author":"MV Meng","year":"2002","unstructured":"Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR (2002) Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60(3):7\u201311","journal-title":"Urology"},{"issue":"4","key":"11289_CR19","doi-asserted-by":"crossref","first-page":"e225432-e","DOI":"10.1001\/jamanetworkopen.2022.5432","volume":"5","author":"ME Suarez-Almazor","year":"2022","unstructured":"Suarez-Almazor ME, Pundole X, Cabanillas G, Lei X, Zhao H, Elting LS et al (2022) Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer. JAMA Net Open 5(4):e225432-e","journal-title":"JAMA Net Open"},{"issue":"7","key":"11289_CR20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-097165","volume":"15","author":"M Ebrahimi","year":"2025","unstructured":"Ebrahimi M, Mohammadi A, Sarmadi S, Rahimnia R, Zare-Kaseb A, Reis LO et al (2025) Prevalence of osteoporosis in prostate cancer survivor patients: a systematic review and meta-analysis protocol. BMJ Open 15(7):e097165","journal-title":"BMJ Open"},{"key":"11289_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"3","key":"11289_CR22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","volume":"42","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42(3):467\u2013475","journal-title":"Bone"},{"issue":"1","key":"11289_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11926-025-01205-9","volume":"27","author":"S Anupama","year":"2025","unstructured":"Anupama S, Lim SY, Bolster MB (2025) Updates on the Role of DXA in the Evaluation and Monitoring of Osteoporosis. Curr Rheumatol Rep 27(1):38","journal-title":"Curr Rheumatol Rep"},{"key":"11289_CR24","volume":"26","author":"WMd Santos","year":"2018","unstructured":"Santos WMd, Secoli SR, P\u00fcschel VAdA (2018) The Joanna Briggs Institute approach for systematic reviews. Rev Lat Am Enferm 26:e3074","journal-title":"Rev Lat Am Enferm"},{"issue":"1","key":"11289_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19264-5","volume":"24","author":"R Sk Abd Razak","year":"2024","unstructured":"Sk Abd Razak R, Ismail A, Abdul Aziz AF, Suddin LS, Azzeri A, Sha\u2019ari NI (2024) Post-COVID syndrome prevalence: a systematic review and meta-analysis. BMC Public Health 24(1):1785","journal-title":"BMC Public Health"},{"issue":"2","key":"11289_CR26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2010) A basic introduction to fixed\u2010effect and random\u2010effects models for meta\u2010analysis. Res Synth Methods 1(2):97\u2013111","journal-title":"Res Synth Methods"},{"key":"11289_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72:1\u201310","journal-title":"Arch Public Health"},{"issue":"7414","key":"11289_CR28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"4","key":"11289_CR29","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1093\/pubmed\/fdac036","volume":"44","author":"MS Cumpston","year":"2022","unstructured":"Cumpston MS, McKenzie JE, Welch VA, Brennan SE (2022) Strengthening systematic reviews in public health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions. J Public Health 44(4):e588\u2013e592","journal-title":"J Public Health"},{"issue":"2","key":"11289_CR30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","volume":"53","author":"A Thornton","year":"2000","unstructured":"Thornton A, Lee P (2000) Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 53(2):207\u2013216","journal-title":"J Clin Epidemiol"},{"issue":"23","key":"11289_CR31","volume":"98","author":"L Shi","year":"2019","unstructured":"Shi L, Lin L (2019) The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore) 98(23):e15987","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"11289_CR32","doi-asserted-by":"crossref","first-page":"28460","DOI":"10.1038\/s41598-024-79888-w","volume":"14","author":"CL Wang","year":"2024","unstructured":"Wang CL, Wang SS, Chen CS, Hung SC, Chen CC, Yang CK, Li JR, Chiu KY, Lin CY (2024) Enhancing screening rates for bone health management in prostate cancer patients on androgen deprivation therapy with an automated outpatient system. Scientific Reports 14(1):28460","journal-title":"Scientific Reports"},{"issue":"4","key":"11289_CR33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.acuroe.2024.02.012","volume":"48","author":"O Legido-G\u00f3mez","year":"2024","unstructured":"Legido-G\u00f3mez O, Rico-Marco S, Lorenzo-S\u00e1nchez MV, Navarro-Jim\u00e9nez S, T\u00e1rraga-Honrubia MA, Mart\u00ednez-Ruiz J et al (2024) Effects of androgen deprivation therapy on elderly men with high-risk prostate cancer: PROSARC observational study. Actas Urol\u00f3gicas Espa\u00f1olas (English Edition) 48(4):304\u2013310","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"},{"issue":"4","key":"11289_CR34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4111\/kju.2009.50.4.327","volume":"50","author":"SI Jung","year":"2009","unstructured":"Jung SI, Kim SO, Kang TW, Kwon DD, Park JY, Cheo J et al (2009) A multicenter prospective study of the risk factors affecting bone mineral density in Korean patients with prostate cancer. Korean J Urol 50(4):327\u2013332","journal-title":"Korean J Urol"},{"issue":"10","key":"11289_CR35","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/cncr.21047","volume":"103","author":"MM Agarwal","year":"2005","unstructured":"Agarwal MM, Khandelwal N, Mandal AK, Rana SV, Gupta V, Mohan VC et al (2005) Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 103(10):2042\u20132052","journal-title":"Cancer"},{"issue":"11","key":"11289_CR36","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/j.lpm.2011.08.002","volume":"40","author":"M Audran","year":"2011","unstructured":"Audran M, Cortet B (2011) Prevalence of osteoporosis in male patients with risk factors. Presse Med 40(11):e489\u2013e498","journal-title":"Presse Med"},{"issue":"6","key":"11289_CR37","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","volume":"167","author":"A Berruti","year":"2002","unstructured":"Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R et al (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167(6):2361\u20132367","journal-title":"J Urol"},{"issue":"1","key":"11289_CR38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.urology.2005.07.017","volume":"67","author":"JM Bruder","year":"2006","unstructured":"Bruder JM, Ma JZ, Basler JW, Welch MD (2006) Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 67(1):152\u2013155","journal-title":"Urology"},{"issue":"2","key":"11289_CR39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1590\/S1677-55382009000200008","volume":"35","author":"SO Kim","year":"2009","unstructured":"Kim SO, Kang TW, Kwon D, Park K, Ryu SB (2009) Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy. Int Braz J Urol 35(2):183\u2013189","journal-title":"Int Braz J Urol"},{"issue":"4","key":"11289_CR40","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.juro.2007.05.135","volume":"178","author":"TL Krupski","year":"2007","unstructured":"Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS (2007) Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 178(4):1423\u20131428","journal-title":"J Urol"},{"issue":"6","key":"11289_CR41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0302-2838(03)00379-8","volume":"44","author":"J Morote","year":"2003","unstructured":"Morote J, Martinez E, Trilla E, Esquena S, Abascal JM, Encabo G et al (2003) Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 44(6):661\u2013665","journal-title":"Eur Urol"},{"issue":"3","key":"11289_CR42","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","volume":"69","author":"J Morote","year":"2007","unstructured":"Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E et al (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69(3):500\u2013504","journal-title":"Urology"},{"issue":"Suppl 2","key":"11289_CR43","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1750-9378-6-S2-S7","volume":"6","author":"BF Morrison","year":"2011","unstructured":"Morrison BF, Burrowes IE, Aiken WD, Mayhew RG, Fletcher HM, Reid ME (2011) Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer. Infect Agent Cancer 6(Suppl 2):S7-S","journal-title":"Infect Agent Cancer"},{"issue":"3","key":"11289_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.pcan.4500520","volume":"4","author":"JL Peters","year":"2001","unstructured":"Peters JL, Fairney A, Kyd P, Patel A, Rogers S, Webster JJ et al (2001) Bone loss associated with the use of LHRH agonists in prostate cancer. Prostate Cancer Prostatic Dis 4(3):161\u2013166","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"11289_CR45","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1464-410X.2006.06695.x","volume":"99","author":"J Planas","year":"2007","unstructured":"Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L et al (2007) The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int 99(4):812\u2013816","journal-title":"BJU Int"},{"issue":"1","key":"11289_CR46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.urology.2007.03.026","volume":"70","author":"CW Ryan","year":"2007","unstructured":"Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT (2007) Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70(1):122\u2013126","journal-title":"Urology"},{"issue":"2","key":"11289_CR47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154\u2013164","journal-title":"N Engl J Med"},{"issue":"3","key":"11289_CR48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jocd.2012.01.010","volume":"15","author":"PR Sieber","year":"2012","unstructured":"Sieber PR, Rommel FM, Theodoran CG, Russinko PJ, Woodward CA, Schimke L (2012) The role of distal third radius dual energy X-ray absorptiometry (DXA) and central DXA in evaluating for osteopenia and osteoporosis in men receiving androgen deprivation therapy for prostate cancer. J Clin Densitom 15(3):351\u2013354","journal-title":"J Clin Densitom"},{"issue":"3","key":"11289_CR49","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jocd.2011.05.003","volume":"14","author":"S Sullivan","year":"2011","unstructured":"Sullivan S, Wagner J, Resnick NM, Nelson J, Perera SK, Greenspan SL (2011) Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer. J Clin Densitom 14(3):348\u2013353","journal-title":"J Clin Densitom"},{"issue":"2","key":"11289_CR50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cncr.20766","volume":"103","author":"T Tanvetyanon","year":"2005","unstructured":"Tanvetyanon T (2005) Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 103(2):237\u2013241","journal-title":"Cancer"},{"issue":"6","key":"11289_CR51","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1464-410X.2009.08483.x","volume":"104","author":"VK Wadhwa","year":"2009","unstructured":"Wadhwa VK, Weston R, Mistry R, Parr NJ (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104(6):800\u2013805","journal-title":"BJU Int"},{"issue":"4","key":"11289_CR52","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1677\/ERC-08-0116","volume":"15","author":"W Wang","year":"2008","unstructured":"Wang W, Yuasa T, Tsuchiya N, Maita S, Kumazawa T, Inoue T et al (2008) Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer 15(4):943\u2013952","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"11289_CR53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(99)00301-5","volume":"54","author":"JT Wei","year":"1999","unstructured":"Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ et al (1999) Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54(4):607\u2013611","journal-title":"Urology"},{"issue":"1","key":"11289_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.pcan.4500846","volume":"9","author":"S Yaturu","year":"2006","unstructured":"Yaturu S, DjeDjos S, Alferos G, Deprisco C (2006) Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy. Prostate Cancer Prostatic Dis 9(1):35\u201338","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"11289_CR55","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s11606-007-0291-4","volume":"22","author":"EFT Yee","year":"2007","unstructured":"Yee EFT, White RE, Murata GH, Handanos C, Hoffman RM (2007) Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med 22(9):1305\u20131310","journal-title":"J Gen Intern Med"},{"issue":"5","key":"11289_CR56","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.urology.2009.10.075","volume":"75","author":"T Yuasa","year":"2010","unstructured":"Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y et al (2010) Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75(5):1131\u20131137","journal-title":"Urology"},{"issue":"9","key":"11289_CR57","first-page":"559","volume":"110","author":"S Ziaran","year":"2009","unstructured":"Ziaran S, Goncalves FM, Wendl J, Trebaticky B, Sn BJ (2009) Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy. Bratislava Med J 110(9):559\u2013562","journal-title":"Bratislava Med J"},{"issue":"10","key":"11289_CR58","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s00198-013-2343-4","volume":"24","author":"SMH Alibhai","year":"2013","unstructured":"Alibhai SMH, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N et al (2013) Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporos Int 24(10):2571\u20132579","journal-title":"Osteoporos Int"},{"issue":"2","key":"11289_CR59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.medcle.2022.03.024","volume":"160","author":"K Ar\u00e9valoRuales","year":"2023","unstructured":"Ar\u00e9valoRuales K, Ivorra Cort\u00e9s J, GrauGarc\u00eda E, Vera Donoso CD, Ca\u00f1adaMart\u00ednez AJ, Rom\u00e1nIvorra JA (2023) Effect of different schemes of androgen deprivation therapy on bone mass density in prostate cancer patients. Medicina Cl\u00ednica (English Edition) 160(2):51\u201359","journal-title":"Medicina Cl\u00ednica (English Edition)"},{"issue":"5","key":"11289_CR60","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.37358\/RC.18.5.6268","volume":"69","author":"V Bojinca","year":"2018","unstructured":"Bojinca V, Popescu C, Balanescu AR, Balanescu SM, Bojinca M (2018) Osteoporosis and bone metabolism in treatment-naive primary prostate adenocarcinoma patients. Rev Chim 69(5):1099\u20131105","journal-title":"Rev Chim"},{"issue":"11","key":"11289_CR61","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1007\/s00520-016-3320-1","volume":"24","author":"R Chahin","year":"2016","unstructured":"Chahin R, Gulamhusein H, Breunis H, Alibhai SMH (2016) Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT). Support Care Cancer 24(11):4713\u20134720","journal-title":"Support Care Cancer"},{"issue":"4","key":"11289_CR62","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.2047-2927.2013.00093.x","volume":"1","author":"AS Cheung","year":"2013","unstructured":"Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D, Ho E et al (2013) Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: Implementation of standardized management guidelines. Andrology 1(4):583\u2013589","journal-title":"Andrology"},{"issue":"1","key":"11289_CR63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jjco\/hyab147","volume":"52","author":"K Hagiwara","year":"2022","unstructured":"Hagiwara K, Sakamoto A, Sasaki K, Kanatani A, Kimura M, Kaneko T et al (2022) Higher serum alkaline phosphatase value indicates the need for bone mineral density testing in non-metastatic prostate cancer patients undergoing androgen deprivation therapy. Jpn J Clin Oncol 52(1):73\u201380","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"11289_CR64","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.6004\/jnccn.2020.7576","volume":"18","author":"J Hu","year":"2020","unstructured":"Hu J, Aprikian AG, Vanhuyse M, Dragomir A (2020) Contemporary population-based analysis of bone mineral density testing in men initiating androgen deprivation therapy for prostate cancer. J Natl Compr Canc Netw 18(10):1374\u20131381","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"11289_CR65","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00774-017-0897-5","volume":"37","author":"S Kato","year":"2019","unstructured":"Kato S, Kawase M, Kato D, Ishida T, Uno M, Fujimoto Y et al (2019) Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy. J Bone Miner Metab 37(1):72\u201380","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"11289_CR66","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12894-016-0151-9","volume":"16","author":"T Kawahara","year":"2016","unstructured":"Kawahara T, Fusayasu S, Izumi K, Yokomizo Y, Ito H, Ito Y, Kurita K, Furuya K, Hasumi H, Hayashi N, Myoshi Y (2016) Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score. BMC Urol 16(1):32","journal-title":"BMC Urol"},{"issue":"2","key":"11289_CR67","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2013.08.045","volume":"83","author":"T Kwon","year":"2014","unstructured":"Kwon T, Jeong IG, Park M, You D, Lee J, Kim HK et al (2014) Bone mineral density in prostate cancer: a comparative study of patients with prostate cancer and healthy controls using propensity score matching. Urology 83(2):385\u2013392","journal-title":"Urology"},{"key":"11289_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/srep39562","volume":"7","author":"SH Kim","year":"2017","unstructured":"Kim SH, Joung JY, Kim S, Rha KH, Kim HG, Kwak C et al (2017) Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study. Sci Rep 7:7","journal-title":"Sci Rep"},{"key":"11289_CR69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejon.2015.10.004","volume":"21","author":"SH Kim","year":"2016","unstructured":"Kim SH, Seong DH, Yoon SM, Choi YD, Song Y, Song H et al (2016) Bone health and its correlates in Korean prostate cancer patients receiving androgen deprivation therapy. Eur J Oncol Nurs 21:197\u2013204","journal-title":"Eur J Oncol Nurs"},{"issue":"1","key":"11289_CR70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1557988315615956","volume":"11","author":"AM Lassemillante","year":"2017","unstructured":"Lassemillante AM, Skinner TL, Hooper JD, Prins JB, Wright ORL (2017) Osteoporosis-Related Health Behaviors in Men With Prostate Cancer and Survivors: Exploring Osteoporosis Knowledge, Health Beliefs, and Self-Efficacy. Am J Mens Health 11(1):13\u201323","journal-title":"Am J Mens Health"},{"issue":"3","key":"11289_CR71","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.aprim.2017.03.006","volume":"50","author":"J Miguel-Carrera","year":"2018","unstructured":"Miguel-Carrera J, Garc\u00eda-Porrua C, de Toro Santos FJ, Picallo-S\u00e1nchez JA (2018) Prevalence of osteoporosis, estimation of probability of fracture and bone metabolism study in patients with newly diagnosed prostate cancer in the health area of Lugo. Aten Primaria 50(3):176\u2013183","journal-title":"Aten Primaria"},{"key":"11289_CR72","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urology.2016.06.024","volume":"96","author":"G Morgia","year":"2016","unstructured":"Morgia G, Russo GI, Tubaro A, Bortolus R, Randone D, Gabriele P et al (2016) Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study. Urology 96:165\u2013170","journal-title":"Urology"},{"issue":"8","key":"11289_CR73","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1464-410X.2012.11777.x","volume":"111","author":"M Nadler","year":"2013","unstructured":"Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM (2013) Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 111(8):1301\u20131309","journal-title":"BJU Int"},{"key":"11289_CR74","doi-asserted-by":"crossref","unstructured":"Nieuwkamer BB, Vrouwe JPM, Willemse PM, Nicolai MPJ, Bevers RFM, Pelger RCM et al (2023) Quantitative ultrasound of the calcaneus (QUS): a valuable tool in the identification of patients with non-metastatic prostate cancer requiring screening for osteoporosis. Bone Rep 18:101679","DOI":"10.1016\/j.bonr.2023.101679"},{"issue":"8","key":"11289_CR75","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.acuro.2017.01.005","volume":"41","author":"S Ojeda","year":"2017","unstructured":"Ojeda S, Lloret M, Naranjo A, D\u00e9niz F, Chesa N, Dom\u00ednguez C et al (2017) Androgen deprivation in prostate cancer and the long-term risk of fracture. Actas Urol Esp 41(8):491\u2013496","journal-title":"Actas Urol Esp"},{"issue":"1","key":"11289_CR76","doi-asserted-by":"crossref","first-page":"493","DOI":"10.21873\/anticanres.16186","volume":"43","author":"I Palumbo","year":"2023","unstructured":"Palumbo I, Ruggiero C, Festa E, de Fano M, Baroni M, Bellavita R et al (2023) Bone Health Care Pathway for Non-metastatic Prostate Cancer Patients on Radiation and Androgen Deprivation Therapy. Anticancer Res 43(1):493\u2013499","journal-title":"Anticancer Res"},{"issue":"4","key":"11289_CR77","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/21681805.2014.884160","volume":"48","author":"MH Poulsen","year":"2014","unstructured":"Poulsen MH, Frost M, Abrahamsen B, Brixen K, Walter S (2014) Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy. Scand J Urol 48(4):350\u2013355","journal-title":"Scand J Urol"},{"issue":"5","key":"11289_CR78","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.rpor.2015.06.004","volume":"20","author":"PM Samper Ots","year":"2015","unstructured":"Samper Ots PM, Mu\u00f1oz Garc\u00eda JL, R\u00edos Kavadoy Y, CouseloPaniagua ML, VillafrancaIturre E, Rodr\u00edguez Li\u00f1\u00e1n M et al (2015) SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study. Rep Pract Oncol Radiother 20(5):370\u2013376","journal-title":"Rep Pract Oncol Radiother"},{"issue":"3","key":"11289_CR79","first-page":"211","volume":"9","author":"A Sharma","year":"2021","unstructured":"Sharma A, Garg G, Sadasukhi N, Sadasukhi TC, Gupta HL, Gupta M et al (2021) A prospective longitudinal study to evaluate bone health, implication of FRAX tool and impact on quality of life (FACT-P) in advanced prostate cancer patients. Am J Clin Exp Urol 9(3):211\u2013220","journal-title":"Am J Clin Exp Urol"},{"issue":"3","key":"11289_CR80","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1590\/s1677-5538.ibju.2019.0023","volume":"46","author":"A Sharma","year":"2020","unstructured":"Sharma A, Sinha RJ, Garg G, Agarwal S, Statistician AA, Singh V (2020) Special emphasis on bone health management in prostate cancer patients: A prospective longitudinal study. Int Braz J Urol 46(3):363\u2013373","journal-title":"Int Braz J Urol"},{"key":"11289_CR81","doi-asserted-by":"crossref","unstructured":"van Oostwaard MM, van den Bergh JP, van de Wouw Y, Janssen-Heijnen M, de Jong M, Wyers CE (2023) High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer. J Bone Oncol. 38","DOI":"10.1016\/j.jbo.2022.100465"},{"issue":"2","key":"11289_CR82","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00198-012-2012-z","volume":"24","author":"M Varsavsky","year":"2013","unstructured":"Varsavsky M, Reyes-Garc\u00eda R, Garc\u00eda-Mart\u00edn A, Gonz\u00e1lez-Ram\u00edrez AR, Avil\u00e9s-Perez MD, Mu\u00f1oz-Torres M (2013) SHBG levels are associated with bone loss and vertebral fractures in patients with prostate cancer. Osteoporos Int 24(2):713\u2013719","journal-title":"Osteoporos Int"},{"issue":"16","key":"11289_CR83","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/pros.24612","volume":"83","author":"S Wu","year":"2023","unstructured":"Wu S, Ma X, Liang Z, Jiang Y, Chen S, Sun G et al (2023) Development and validation of a nomogram for predicting osteoporosis in prostate cancer patients: a cross-sectional study from China. Prostate 83(16):1537\u20131548","journal-title":"Prostate"},{"issue":"2","key":"11289_CR84","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12020-015-0536-7","volume":"50","author":"A-CM Lassemillante","year":"2015","unstructured":"Lassemillante A-CM, Doi SAR, Hooper JD, Prins JB, Wright ORL (2015) Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocrine 50(2):344\u2013354","journal-title":"Endocrine"},{"issue":"3","key":"11289_CR85","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12020-013-0083-z","volume":"45","author":"A-CM Lassemillante","year":"2014","unstructured":"Lassemillante A-CM, Doi SAR, Hooper JD, Prins JB, Wright ORL (2014) Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine 45(3):370\u2013381","journal-title":"Endocrine"},{"issue":"1","key":"11289_CR86","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L, Behzadi M, Rabieenia E, Shohaimi S et al (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16(1):609","journal-title":"J Orthop Surg Res"},{"key":"11289_CR87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/ijpvm.IJPVM_657_20","volume":"13","author":"H Nourmohammadi","year":"2022","unstructured":"Nourmohammadi H, Abdan Z, Amin Hashemipour SM, Sarokhani D, Abdan M, Fakhri M et al (2022) Prevalence of osteoporosis and osteopenia in people over 60 years in Iran: a systematic review and meta-analysis. Int J Prev Med 13:11","journal-title":"Int J Prev Med"},{"issue":"4","key":"11289_CR88","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S2213-8587(22)00012-2","volume":"10","author":"T Vilaca","year":"2022","unstructured":"Vilaca T, Eastell R, Schini M (2022) Osteoporosis in men. Lancet Diabet Endocrinol 10(4):273\u2013283","journal-title":"Lancet Diabet Endocrinol"},{"issue":"4","key":"11289_CR89","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3390\/ijms22042105","volume":"22","author":"G Rinonapoli","year":"2021","unstructured":"Rinonapoli G, Ruggiero C, Meccariello L, Bisaccia M, Ceccarini P, Caraffa A (2021) Osteoporosis in men: a review of an underestimated bone condition. Int J Mol Sci 22(4):2105","journal-title":"Int J Mol Sci"},{"key":"11289_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174305","author":"E Boopathi","year":"2022","unstructured":"Boopathi E, Birbe R, Shoyele SA, Den RB, Thangavel C (2022) Bone health management in the continuum of prostate cancer disease. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14174305","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11289_CR91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.31083\/j.fbl2701034","volume":"27","author":"MA G\u00f3mez-Aparicio","year":"2022","unstructured":"G\u00f3mez-Aparicio MA, L\u00f3pez-Campos F, Pelari-Mici L, Buchser D, Pastor J, Maldonado X et al (2022) Bone health and therapeutic agents in advanced prostate cancer. Front Biosci-Landmark 27(1):34","journal-title":"Front Biosci-Landmark"},{"key":"11289_CR92","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100465","volume":"38","author":"MM van Oostwaard","year":"2023","unstructured":"van Oostwaard MM, van den Bergh JP, van de Wouw Y, Janssen-Heijnen M, de Jong M, Wyers CE (2023) High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer. J Bone Oncol 38:100465","journal-title":"J Bone Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11289-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11289-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11289-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:48:08Z","timestamp":1792086488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11289-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11289"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11289-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no materials from other sources.","order":2,"name":"Ethics","label":"Permission to reproduce material from other sources","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the revision of this manuscript, the authors used Claude (Anthropic) solely to improve its language, grammar, clarity, and readability. The AI-assisted suggestions were critically reviewed and edited by the authors, who retained full responsibility for the accuracy, integrity, interpretation, and final content of the manuscript.","order":5,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1053"}}